The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Open accessPublished version of a preprint
Abstract
We show, in a series of established experimental breast adenocarcinomas and fibrosarcomas induced by carcinogen de novo in mice, that the therapeutic efficacy of doxorubicin treatment is dependent on CD8 T cells and IFN-γ production. Doxorubicin treatment enhances tumor antigen–specific proliferation of CD8 T cells in tumor-draining lymph nodes and promotes tumor infiltration of activated, IFN-γ–producing CD8 T cells. Optimal doxorubicin treatment outcome also requires both interleukin (IL)-1β and IL-17 cytokines, as blockade of IL-1β/IL-1R or IL-17A/IL-17Rα signaling abrogated the therapeutic effect. IL-23p19 had no observed role. The presence of γδ T cells, but not Jα18+ natural killer T cells, at the time of doxorubicin treatment was also important. In tumor samples taken from breast cancer patients prior to treatment with anthracycline chemotherapy, a correlation between CD8α, CD8β, and IFN-γ gene expression levels and clinical response was observed, supporting their role in the therapeutic efficacy of anthracyclines in humans. Overall, these data strongly support the pivotal contribution of both innate and adaptive immunity in treatment outcomes of anthracycline chemotherapy. Cancer Res; 71(14); 4809–20. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“These include translocation of the endoplasmic reticulum resident calreticulin complex to the plasma membrane, providing an ‘eatme’ signal (5-7) and release of the nuclear alarmin HMGB1 to engage TLR-4 on dendritic cells (DC) (8, 9).”
BackgroundSelf-citationMAQC Consortium, Shi, L., Shi, L., Reid, L. H., Jones, W. D., Shippy, R., Warrington, J. A., Baker, S. C., Collins, P. J., de Longueville, F., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1239 · Cited by 2,126
Self-citationGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationCaspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Self-citationDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Self-citationThe co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344
Self-citation
Research works printed but not linked: 41
- Rasmussen, 1982, Chemotherapy-induced immunosuppression, Environ Health Perspect, 43, 21, 10.1289/ehp.824321 · DOI
- Steele, 2002, Chemotherapy-induced immunosuppression and reconstitution of immune function, Leuk Res, 26, 411, 10.1016/S0145-2126(01)00138-2 · DOI
- Ma, 2010, Chemotherapy and radiotherapy: cryptic anticancer vaccines, Semin Immunol, 22, 113, 10.1016/j.smim.2010.03.001 · DOI · Paper page
- Haynes, 2008, Immunogenic anti-cancer chemotherapy as an emerging concept, Curr Opin Immunol, 20, 545, 10.1016/j.coi.2008.05.008 · DOI
- Guerriero, 2011, DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity, J Immunol, 186, 3517, 10.4049/jimmunol.1003267 · DOI
- Orsini, 1977, Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice, Cancer Res, 37, 1719
- Schwartz, 1973, Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression, Cancer Res, 33, 1837
- Maccubbin, 1990, Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions, Cancer Immunol Immunother, 31, 373, 10.1007/BF01741409 · DOI
- Smyth, 2000, Differential tumor surveillance by natural killer (NK) and NKT cells, J Exp Med, 191, 661, 10.1084/jem.191.4.661 · DOI · Paper page
- Teng, 2010, Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion, Cancer Res, 70, 2665, 10.1158/0008-5472.CAN-09-1574 · DOI
- Stagg, 2010, Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis, Proc Natl Acad Sci U S A, 107, 1547, 10.1073/pnas.0908801107 · DOI · Paper page
- Stagg, 2008, Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response, Proc Natl Acad Sci U S A, 105, 16254, 10.1073/pnas.0806849105 · DOI
- Swann, 2008, Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis, Proc Natl Acad Sci U S A, 105, 652, 10.1073/pnas.0708594105 · DOI · Paper page
- van de Vijver, 2002, A gene-expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999, 10.1056/NEJMoa021967 · DOI · Paper page
- Wang, 2005, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer, Lancet, 365, 671, 10.1016/S0140-6736(05)17947-1 · DOI · Paper page
- Schmidt, 2008, The humoral immune system has a key prognostic impact in node-negative breast cancer, Cancer Res, 68, 5405, 10.1158/0008-5472.CAN-07-5206 · DOI · Paper page
- Desmedt, 2007, Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series, Clin Cancer Res, 13, 3207, 10.1158/1078-0432.CCR-06-2765 · DOI · Paper page
- Haibe-Kains, 2010, A fuzzy gene expression-based computational approach improves breast cancer prognostication, Genome Biol, 11, R18, 10.1186/gb-2010-11-2-r18 · DOI
- Loi, 2010, PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer, Proc Natl Acad Sci U S A, 107, 10208, 10.1073/pnas.0907011107 · DOI · Paper page
- Wirapati, 2008, Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures, Breast Cancer Res, 10, R65, 10.1186/bcr2124 · DOI · Paper page
- Desmedt, 2011, Multifactorial approach to predicting resistance to anthracyclines, J Clin Oncol, 29, 1578, 10.1200/JCO.2010.31.2231 · DOI · Paper page
- Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 · DOI · Paper page
- Naito, 1998, CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer, Cancer Res, 58, 3491
- Street, 2002, Suppression of lymphoma and epithelial malignancies effected by interferon gamma, J Exp Med, 196, 129, 10.1084/jem.20020063 · DOI · Paper page
- Teng, 2010, IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis, Proc Natl Acad Sci U S A, 107, 8328, 10.1073/pnas.1003251107 · DOI
- Uno, 2006, Eradication of established tumors in mice by a combination antibody-based therapy, Nat Med, 12, 693, 10.1038/nm1405 · DOI · Paper page
- Rachitskaya, 2008, Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion, J Immunol, 180, 5167, 10.4049/jimmunol.180.8.5167 · DOI · Paper page
- Sutton, 2009, Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity, Immunity, 31, 331, 10.1016/j.immuni.2009.08.001 · DOI · Paper page
- van Beelen, 2007, Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells, Immunity, 27, 660, 10.1016/j.immuni.2007.08.013 · DOI · Paper page
- Crowe, 2002, A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas, J Exp Med, 196, 119, 10.1084/jem.20020092 · DOI · Paper page
- Gao, 2003, Gamma delta T cells provide an early source of interferon gamma in tumor immunity, J Exp Med, 198, 433, 10.1084/jem.20030584 · DOI · Paper page
- Wolmark, 2001, Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18, J Natl Cancer Inst Monogr, 96, 10.1093/oxfordjournals.jncimonographs.a003469 · DOI · Paper page
- Ma, 2011, Contribution of IL-17-producing {gamma}{delta} T cells to the efficacy of anticancer chemotherapy, J Exp Med, 208, 491, 10.1084/jem.20100269 · DOI · Paper page
- Ladoire, 2011, In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, J Pathol, 10.1002/path.2866 · DOI · Paper page
- Doisne, 2011, Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1-invariant NKT cells to bacteria, J Immunol, 186, 662, 10.4049/jimmunol.1002725 · DOI
- Umemura, 2007, IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection, J Immunol, 178, 3786, 10.4049/jimmunol.178.6.3786 · DOI · Paper page
- Teng, 2011, Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases, Cancer Res, 71, 2077, 10.1158/0008-5472.CAN-10-3994 · DOI
- Kortylewski, 2009, Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment, Cancer Cell, 15, 114, 10.1016/j.ccr.2008.12.018 · DOI · Paper page
- Stewart, 2009, Reinforcing suppression using regulators: a new link between STAT3, IL-23, and Tregs in tumor immunosuppression, Cancer Cell, 15, 81, 10.1016/j.ccr.2009.01.008 · DOI
- Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370 · DOI · Paper page
- Hornychova, 2008, Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma, Cancer Invest, 26, 1024, 10.1080/07357900802098165 · DOI
Cited by
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationLoi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Self-citationLoi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Self-citationAutophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Metadata
- Authors
- Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J.
- Venue
- Cancer Research
- Published
- 2011-07-14
- Volume
- 71
- Issue
- 14
- Pages
- 4809-4820
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2158545805
- Cited by
- 333
- References
- 9
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-0753
- The paper
- Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011). Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-0753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.